Literature DB >> 8240011

The mumps virus V protein is unstable in virus infected cells.

A Hu1, S Schwartz, G Utter, C Orvell, J Kövamees, E Norrby.   

Abstract

The mumps virus (MuV) V protein was characterized in virus infected cells by the use of antipeptide sera. In radioimmune precipitation assay (RIPA), the sera reacted with the V protein and also immunoprecipitated the nucleocapsid (NP) and phospho (P) proteins. However, by depletion RIPA (in which either the NP and P proteins or the V protein were removed) and Western immunoblotting, it was demonstrated that the V protein was not associated with the NP and P proteins, but that the anti-V sera cross-reacted with the NP protein. Pulse-chase experiments demonstrated that the V protein was gradually decreased during the chase period and could not be detected by antibodies raised against peptides representing three different regions of the protein at the end of the chase, while the NP and P proteins were relatively stable during the chase period. These results suggest that the V protein is unstable and degraded gradually in virus infected cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240011     DOI: 10.1007/bf01309756

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  25 in total

1.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

2.  The P gene of the porcine paramyxovirus LPMV encodes three possible polypeptides P, V and C: the P protein mRNA is edited.

Authors:  M Berg; B Hjertner; J Moreno-López; T Linné
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

3.  Simplified procedure for carrying out simultaneous multiple hydrogen fluoride cleavages of protected peptide resins.

Authors:  R A Houghten; M K Bray; S T Degraw; C J Kirby
Journal:  Int J Pept Protein Res       Date:  1986-06

4.  Monoclonal antibodies against five structural components of measles virus. I. Characterization of antigenic determinants on nine strains of measles virus.

Authors:  H Sheshberadaran; S N Chen; E Norrby
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

5.  A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop.

Authors:  B Akerlind-Stopner; G Utter; M A Mufson; C Orvell; R A Lerner; E Norrby
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

6.  Characterization of V protein in measles virus-infected cells.

Authors:  E A Wardrop; D J Briedis
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

7.  The reactions of monoclonal antibodies with structural proteins of mumps virus.

Authors:  C Orvell
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

8.  Two mRNAs that differ by two nontemplated nucleotides encode the amino coterminal proteins P and V of the paramyxovirus SV5.

Authors:  S M Thomas; R A Lamb; R G Paterson
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

9.  The P gene of bovine parainfluenza virus 3 expresses all three reading frames from a single mRNA editing site.

Authors:  T Pelet; J Curran; D Kolakofsky
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

10.  RNA editing in the phosphoprotein gene of the human parainfluenza virus type 3.

Authors:  M S Galinski; R M Troy; A K Banerjee
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

View more
  2 in total

1.  Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1.

Authors:  Lenette L Lu; Mamta Puri; Curt M Horvath; Ganes C Sen
Journal:  J Biol Chem       Date:  2008-03-24       Impact factor: 5.157

2.  Control of the induction of type I interferon by Peste des petits ruminants virus.

Authors:  Beatriz Sanz Bernardo; Stephen Goodbourn; Michael D Baron
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.